| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HbA1c |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | N |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的3篇关于HbA1c重组蛋白的参考文献(注：文献为虚构示例，实际研究请通过学术数据库检索)：
1. **文献名称**: "Production and Characterization of Recombinant Human Hemoglobin A1c for Diagnostic Assays"
**作者**: Zhang, L., et al.
**摘要**: 该研究报道了在大肠杆菌表达系统中重组表达人HbA1c蛋白的方法，通过体外糖化修饰模拟天然结构，证实其与临床样本的免疫反应性一致，可作为糖尿病检测试剂盒的校准标准品。
2. **文献名称**: "Structural Analysis of Recombinant Glycated Hemoglobin Using Mass Spectrometry"
**作者**: Tanaka, K., et al.
**摘要**: 研究团队利用杆状病毒-昆虫细胞系统表达重组HbA1c，并通过质谱分析其糖化位点与修饰程度，证明重组蛋白与患者血液中分离的HbA1c具有相同的分子特征，适用于精准检测方法的开发。
3. **文献名称**: "Stability Evaluation of Recombinant HbA1c Reference Materials under Different Storage Conditions"
**作者**: Gupta, R., & Singh, M.
**摘要**: 对比分析了哺乳动物细胞和原核系统表达的重组HbA1c在不同温度与湿度下的稳定性，发现真核表达产物在长期储存中糖化结构更稳定，为体外诊断试剂的质控提供数据支持。
建议通过PubMed或Web of Science以关键词 "recombinant HbA1c protein" "glycated hemoglobin production" 检索最新实证研究。
Hemoglobin A1c (HbA1c), a glycated form of hemoglobin, serves as a critical biomarker for assessing long-term glycemic control in individuals with diabetes. It forms when glucose non-enzymatically binds to the N-terminal valine of hemoglobin’s beta chain, a process influenced by blood glucose levels and erythrocyte lifespan. Clinically, HbA1c reflects average blood glucose concentrations over the preceding 8–12 weeks, making it indispensable for diabetes diagnosis and management.
Recombinant HbA1c protein is engineered to mimic this natural glycation structure in vitro, addressing challenges in standardizing HbA1c measurements across diagnostic assays. Traditional methods to source HbA1c rely on isolating it from human blood, which introduces variability due to donor differences and instability during storage. Recombinant technology overcomes these limitations by producing uniform, high-purity HbA1c through heterologous expression systems, such as E. coli or mammalian cell lines. The protein is typically modified to incorporate glycation at specific residues, ensuring consistency in epitope presentation for immunoassays or chromatographic calibration.
Applications of recombinant HbA1c span diagnostics, quality control, and research. It is widely used to calibrate lab instruments, validate test kits, and develop antibodies with high specificity. Additionally, it supports studies exploring glycation mechanisms or evaluating therapeutic interventions targeting hyperglycemia. By providing a scalable and reproducible standard, recombinant HbA1c enhances the accuracy and reliability of global diabetes monitoring, aligning with efforts to harmonize clinical guidelines and improve patient outcomes. Its role in advancing precision medicine underscores its importance in both biomedical research and healthcare systems.
×
